Literature DB >> 18375075

Acute toxicity after hypofractionated conformal radiotherapy for localized prostate cancer: nonrandomized contemporary comparison with standard fractionation.

Felix Leborgne1, Jack Fowler.   

Abstract

PURPOSE: To prospectively study acute rectal and urinary reactions from three-dimensional conformal external beam radiotherapy for localized prostate cancer comparing two hypofractionation regimens with standard fractionation (standard). The hypofractionation regimens were designed to avoid more late reactions in the hypofractionation groups than in the standard group, with the advantage of one-half as many treatment sessions. PATIENTS AND MATERIALS: A total of 56 nonrandomized patients chose hypofractionation delivered at 3 (n = 22) or 3.15 (n = 34) Gy/fraction, 4 d/wk, to a total dose of 60 or 63 Gy within 5 weeks. A total of 74 patients were contemporarily treated with standard fractionation at 2 Gy/fraction, 5 d/wk, to a total dose of 76 to 80 Gy.
RESULTS: The differences within patients without complications were not statistically significant in the three groups. However, for acute complications of Grade 2 or worse, the Hypo3.15 group had significantly greater (p = 0.001) complication rates (50%) compared with the standard group (17%). The incidence of patients without acute rectal complications was significantly lower for the Hypo3.15 group compared with the Hypo3 and standard groups. The incidence of rectal Grade 2 or greater complications was correspondingly significantly greater for the Hypo3.15 group than for the Hypo3 and standard groups (p < 0.001). The incidence of patients with urinary complications was not significantly different among the three groups.
CONCLUSIONS: Acute rectal reactions were more frequent and intense in the Hypo3.15 group than in the Hypo3 and standard groups. In our study, 60 Gy at 3 Gy/fraction within 5 weeks resulted in acute toxicity similar to that after standard fractionation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18375075     DOI: 10.1016/j.ijrobp.2008.01.023

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Acute toxicity of hypofractionated intensity-modulated radiotherapy for prostate cancer.

Authors:  C S Drodge; O Boychak; S Patel; N Usmani; J Amanie; M B Parliament; A Murtha; C Field; S Ghosh; N Pervez
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

2.  Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06.

Authors:  Susan L Tucker; Jeff M Michalski; Walter R Bosch; Radhe Mohan; Lei Dong; Kathryn Winter; James A Purdy; James D Cox
Journal:  Radiother Oncol       Date:  2012-06-05       Impact factor: 6.280

Review 3.  Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials.

Authors:  Víctor Macías; Albert Biete
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

4.  Prognostic factors for acute toxicity in prostate cancer patients treated with high-dose hypofractionated radiotherapy.

Authors:  V Macias; R Gonzalez Celador; C Marti-Macia; C Cigarral; L A Perez-Romasanta
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

5.  A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.

Authors:  Darius Norkus; Albert Miller; Juozas Kurtinaitis; Uwe Haverkamp; Sergey Popov; Franz-Josef Prott; Konstantinas Povilas Valuckas
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

Review 6.  The case for hypofractionation of localized prostate cancer.

Authors:  Winnifred M Wong; Kent E Wallner
Journal:  Rev Urol       Date:  2013

7.  Endo-rectal balloon cavity dosimetry in a phantom: performance under IMRT and helical tomotherapy beams.

Authors:  Nicholas Hardcastle; Peter E Metcalfe; Anatoly B Rosenfeld; Wolfgang A Tomé
Journal:  Radiother Oncol       Date:  2009-03-30       Impact factor: 6.280

8.  Phase II Trial of Pure Hypofractionated Radiotherapy in the Treatment of Localized Carcinoma of the Prostate.

Authors:  Darin Gopaul; Dilip Panjwani; Robert F Stephens; Michael Lock
Journal:  Cureus       Date:  2018-10-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.